Scribe Therapeutics filed IPO paperwork to fund a clinical push for lipid-lowering genetic medicines, with proceeds earmarked for its lead PCSK9-targeting gene-silencing program STX-1150 and follow-on assets. The company said it expects to raise about $96 million at a planned $13–$15 per share range, subject to final pricing. STX-1150 is designed to shut down PCSK9, a target already addressed by approved cholesterol therapies such as Amgen’s Repatha and Novartis’ Leqvio. Scribe has initiated a first-in-human study in Australia with up to 64 adults with elevated LDL-C and increased atherosclerotic cardiovascular disease risk, with topline LDL-C reduction readouts expected in the first half of 2027. Scribe also outlined plans to move STX-1400, targeting APOC3, and advance preclinical STX-1200, targeting LPA, into the clinic using additional IPO proceeds.